Martinez Bueno A, Molina MA, Fielding A, et al. Disruptive mutations in TP53 associate with survival benefit in a PARPi trial in ovarian cancer. ESMO 2017, abstract LBA42.
COVID-19-mortaliteit bij kankerpatiënten - impact van behandeling
aug 2020 | Immuuntherapie